Epiberberine

Epiberberine at a Glance

Epiberberine is a quaternary protoberberine isoquinoline alkaloid and a minor constituent of goldthread (Coptis, Huanglian) rhizome. It is one of the five signature Coptis alkaloids — with berberine, coptisine, palmatine and jatrorrhizine — that together define the plant’s chemistry and are routinely quantified to assess the quality of Rhizoma Coptidis ^{7,8Reference 7Lv X et al. · 2016Integration of HPLC-based fingerprint and quantitative analyses for differentiating botanical species and geographical growing origins of Rhizoma coptidisView study →Reference 8Meng FC et al. · 2018Coptidis rhizoma and its main bioactive components: recent advances in chemical investigation, quality evaluation and pharmacological activityView study →}.

Its own pharmacology is entirely preclinical. Isolated epiberberine shows anti-Helicobacter pylori, anti-diabetic, kidney-protective, anti-steatotic and acetylcholinesterase-inhibiting activity in cell and rodent studies ^{1,2,3,4,5Reference 1Wu H et al. · 2024In vitroEpiberberine inhibits Helicobacter pylori and reduces host apoptosis and inflammatory damage by down-regulating urease expression — in vitro and mouse modelView study →Reference 2Zhang S et al. · 2024AnimalActivation of NRF2 by epiberberine improves oxidative stress and insulin resistance in T2DM mice and IR-HepG2 cells in an AMPK-dependent mannerView study →Reference 3Xiao Y et al. · 2021Epiberberine ameliorated diabetic nephropathy by inactivating the angiotensinogen (Agt) to repress TGFβ/Smad2 pathwayView study →Reference 4Zhou LM et al. · 2023Epiberberine regulates lipid synthesis through SHP (NR0B2) to improve non-alcoholic steatohepatitisView study →Reference 5Kong XP et al. · 2019Synergistic inhibition of acetylcholinesterase by alkaloids derived from Stephaniae Tetrandrae Radix, Coptidis Rhizoma and Phellodendri Chinensis CortexView study →}. There are no human trials of epiberberine as an isolate, and most of what is known clinically about Coptis belongs to its dominant alkaloid, berberine — not to epiberberine.

One pharmacokinetic point sets it apart from berberine: epiberberine is a positional isomer that is reasonably well absorbed by mouth (absolute oral bioavailability ~14% in rats) and, importantly, does not convert to berberine in the body — so the two isomers are genuinely distinct molecules with distinct behaviour, not interchangeable labels ^{6Reference 6Chen N et al. · 2018In vitroThe oral bioavailability, excretion and cytochrome P450 inhibition properties of epiberberine: an in vivo and in vitro evaluationView study →}.

One of Coptis’s Five Alkaloids

Epiberberine’s most established real-world role is analytical, not therapeutic. Goldthread rhizome (Huanglian) is a multi-alkaloid crude drug, and its quality is judged by the combined content of berberine, coptisine, palmatine, epiberberine and jatrorrhizine — the five protoberberine-type alkaloids measured together by HPLC (and by UPLC, near-infrared and other methods) to authenticate the botanical species, distinguish geographical origins, and grade commercial material ^{7,8Reference 7Lv X et al. · 2016Integration of HPLC-based fingerprint and quantitative analyses for differentiating botanical species and geographical growing origins of Rhizoma coptidisView study →Reference 8Meng FC et al. · 2018Coptidis rhizoma and its main bioactive components: recent advances in chemical investigation, quality evaluation and pharmacological activityView study →}.

In that five-marker panel, epiberberine is a minor component: in Coptis chinensis rhizome it runs at roughly 1.1–1.4% of dry weight (~11–14 mg/g), well below berberine, which can reach ~5–8% ^{7Reference 7Lv X et al. · 2016Integration of HPLC-based fingerprint and quantitative analyses for differentiating botanical species and geographical growing origins of Rhizoma coptidisView study →}. Its ratio to the other alkaloids varies by Coptis species (C. chinensis, C. deltoidea, C. teeta), plant part and growing region, which is exactly why the marker panel is useful for telling sources apart ^{7Reference 7Lv X et al. · 2016Integration of HPLC-based fingerprint and quantitative analyses for differentiating botanical species and geographical growing origins of Rhizoma coptidisView study →}.

The practical takeaway: whenever you see epiberberine named, it is almost always as one line in a Coptis alkaloid profile — a chemical fingerprint of the plant — rather than as a stand-alone ingredient.

What It's Used For

Epiberberine’s research base is small, mechanism-focused and preclinical throughout — cell lines and mice, all on the isolated molecule. The honest frame is that these are early signals for a minor Coptis alkaloid, not an established therapy; where Coptis has genuine human data, that data is for berberine.

Evidence by IndicationStrength of support · Beta

Support is an experimental score — weighted by study type (human > animal > in vitro) and volume. A beta, not a validated metric. Every row here is preclinical (cell/rodent, isolated molecule), so scores stay low by design; there is no human column to earn.

01Anti-Helicobacter pyloriShaky40%In-vitro + mouse; urease/ureB down-regulation mechanism ^{1Reference 1Wu H et al. · 2024In vitroEpiberberine inhibits Helicobacter pylori and reduces host apoptosis and inflammatory damage by down-regulating urease expression — in vitro and mouse modelView study →}

02Glycaemic control / insulin resistanceShaky34%T2DM mice + IR-HepG2 cells; NRF2–AMPK ^{2Reference 2Zhang S et al. · 2024AnimalActivation of NRF2 by epiberberine improves oxidative stress and insulin resistance in T2DM mice and IR-HepG2 cells in an AMPK-dependent mannerView study →}

03Diabetic nephropathyShaky30%db/db mice + cells; Agt–TGFβ/Smad2 ^{3Reference 3Xiao Y et al. · 2021Epiberberine ameliorated diabetic nephropathy by inactivating the angiotensinogen (Agt) to repress TGFβ/Smad2 pathwayView study →}

04Fatty liver / steatohepatitisShaky28%MCD-diet mice + HepG2; SHP/NR0B2 → ↓SREBP-1c/FASN ^{4Reference 4Zhou LM et al. · 2023Epiberberine regulates lipid synthesis through SHP (NR0B2) to improve non-alcoholic steatohepatitisView study →}

05Acetylcholinesterase inhibitionShaky24%In-vitro enzyme assay; moderate vs other Coptis alkaloids ^{5Reference 5Kong XP et al. · 2019Synergistic inhibition of acetylcholinesterase by alkaloids derived from Stephaniae Tetrandrae Radix, Coptidis Rhizoma and Phellodendri Chinensis CortexView study →}

Mechanisms

The metabolic mechanisms (AMPK, SREBP-1c/FASN) echo berberine’s, which is unsurprising for a co-occurring protoberberine; the urease and Agt/TGFβ findings are the more epiberberine-specific results.

Pharmacokinetics

This is where epiberberine most clearly diverges from its famous isomer. In rats, epiberberine is rapidly absorbed (Tmax ~0.4 h) and has an absolute oral bioavailability of about 14% — an order of magnitude higher than berberine’s <1% — and it is stable in vivo, not metabolised into berberine ^{6Reference 6Chen N et al. · 2018In vitroThe oral bioavailability, excretion and cytochrome P450 inhibition properties of epiberberine: an in vivo and in vitro evaluationView study →}. It is eliminated largely via bile/faeces and the kidneys, with possible enterohepatic recycling ^{6Reference 6Chen N et al. · 2018In vitroThe oral bioavailability, excretion and cytochrome P450 inhibition properties of epiberberine: an in vivo and in vitro evaluationView study →}. In the same work epiberberine inhibited CYP2C9 and CYP2D6 (noncompetitively, and more strongly in human than rat liver microsomes), which is the basis of its main theoretical drug-interaction caution ^{6Reference 6Chen N et al. · 2018In vitroThe oral bioavailability, excretion and cytochrome P450 inhibition properties of epiberberine: an in vivo and in vitro evaluationView study →}. The practical reading: unlike berberine — whose story is dominated by poor absorption and gut/liver-local action — epiberberine actually reaches the circulation to a meaningful degree, though what that means clinically is untested.

Clinical Trials

There are no clinical trials of isolated epiberberine — completed, ongoing or registered. All human-relevant Coptis trial evidence is for berberine (metabolic and gastrointestinal indications), where epiberberine is only a minor co-occurring alkaloid.

Last checked: July 2026.

Isolate vs. Plant Studies

Every epiberberine finding above is on the isolated molecule in cells or mice ^{1,2,3,4,5Reference 1Wu H et al. · 2024In vitroEpiberberine inhibits Helicobacter pylori and reduces host apoptosis and inflammatory damage by down-regulating urease expression — in vitro and mouse modelView study →Reference 2Zhang S et al. · 2024AnimalActivation of NRF2 by epiberberine improves oxidative stress and insulin resistance in T2DM mice and IR-HepG2 cells in an AMPK-dependent mannerView study →Reference 3Xiao Y et al. · 2021Epiberberine ameliorated diabetic nephropathy by inactivating the angiotensinogen (Agt) to repress TGFβ/Smad2 pathwayView study →Reference 4Zhou LM et al. · 2023Epiberberine regulates lipid synthesis through SHP (NR0B2) to improve non-alcoholic steatohepatitisView study →Reference 5Kong XP et al. · 2019Synergistic inhibition of acetylcholinesterase by alkaloids derived from Stephaniae Tetrandrae Radix, Coptidis Rhizoma and Phellodendri Chinensis CortexView study →} — there is essentially no body of “epiberberine-standardised extract” human work, and no human isolate trials either. The whole-plant relationship runs through goldthread (Coptis / Huanglian), a multi-alkaloid rhizome in which berberine dominates and epiberberine is a minor partner ^{7,8Reference 7Lv X et al. · 2016Integration of HPLC-based fingerprint and quantitative analyses for differentiating botanical species and geographical growing origins of Rhizoma coptidisView study →Reference 8Meng FC et al. · 2018Coptidis rhizoma and its main bioactive components: recent advances in chemical investigation, quality evaluation and pharmacological activityView study →}. So the correct framing is: epiberberine contributes to Coptis’s total-alkaloid activity (the anti-H. pylori urease work explicitly points to a multi-alkaloid effect ^{1Reference 1Wu H et al. · 2024In vitroEpiberberine inhibits Helicobacter pylori and reduces host apoptosis and inflammatory damage by down-regulating urease expression — in vitro and mouse modelView study →}), but the plant’s human evidence — and most of its reputation — belongs to berberine, not to this isomer. Read epiberberine as a mechanistically interesting minor alkaloid, not as the active principle of goldthread.

Prevalence in Nature

Epiberberine is largely restricted to the genus Coptis (Ranunculaceae) — the goldthreads / Huanglian — where it is a minor member of the protoberberine alkaloid pool alongside berberine, coptisine, palmatine and jatrorrhizine ^{7,8Reference 7Lv X et al. · 2016Integration of HPLC-based fingerprint and quantitative analyses for differentiating botanical species and geographical growing origins of Rhizoma coptidisView study →Reference 8Meng FC et al. · 2018Coptidis rhizoma and its main bioactive components: recent advances in chemical investigation, quality evaluation and pharmacological activityView study →}. It concentrates in the rhizome rather than the leaves, in keeping with the alkaloid-storage pattern of the group.

Quantitatively it is well below berberine: in Coptis chinensis rhizome, HPLC studies report epiberberine at roughly 1.1–1.4% of dry weight (~11–14 mg/g), versus berberine’s ~5–8% ^{7Reference 7Lv X et al. · 2016Integration of HPLC-based fingerprint and quantitative analyses for differentiating botanical species and geographical growing origins of Rhizoma coptidisView study →}. Its content — and its ratio to the other four marker alkaloids — shifts with Coptis species (C. chinensis, C. deltoidea, C. teeta), plant part and geographical origin, which is precisely what makes the five-alkaloid fingerprint useful for authenticating and grading the crude drug ^{7,8Reference 7Lv X et al. · 2016Integration of HPLC-based fingerprint and quantitative analyses for differentiating botanical species and geographical growing origins of Rhizoma coptidisView study →Reference 8Meng FC et al. · 2018Coptidis rhizoma and its main bioactive components: recent advances in chemical investigation, quality evaluation and pharmacological activityView study →}.

Major Natural Sources

Source	Plant part	Reported epiberberine content
Chinese goldthread (Coptis chinensis)	rhizome	~1.1–1.4% dry wt (~11–14 mg/g)
Coptis deltoidea	rhizome	present; species-dependent ratio
Yunnan goldthread (Coptis teeta)	rhizome	present; species-dependent ratio

These are figures for the Coptis rhizome (Huanglian), and the exact levels vary with species, origin and analytical method ^{7,8Reference 7Lv X et al. · 2016Integration of HPLC-based fingerprint and quantitative analyses for differentiating botanical species and geographical growing origins of Rhizoma coptidisView study →Reference 8Meng FC et al. · 2018Coptidis rhizoma and its main bioactive components: recent advances in chemical investigation, quality evaluation and pharmacological activityView study →}.

Discovery & Synthesis

Epiberberine is a long-recognised minor alkaloid of Coptis (Huanglian), catalogued as one of the genus’s characteristic protoberberines (CAS 6873-09-2); a specific first-isolation date and discoverer are not well pinned in the accessible literature, and it entered modern research chiefly as one of the alkaloids resolved by chromatographic study of Rhizoma Coptidis ^{7,8Reference 7Lv X et al. · 2016Integration of HPLC-based fingerprint and quantitative analyses for differentiating botanical species and geographical growing origins of Rhizoma coptidisView study →Reference 8Meng FC et al. · 2018Coptidis rhizoma and its main bioactive components: recent advances in chemical investigation, quality evaluation and pharmacological activityView study →}. Structurally it is a positional isomer of berberine (the two differ only in the placement of the methylenedioxy and methoxy substituents on the aromatic rings), which is why the two are easily confused yet behave differently in the body ^{6Reference 6Chen N et al. · 2018In vitroThe oral bioavailability, excretion and cytochrome P450 inhibition properties of epiberberine: an in vivo and in vitro evaluationView study →}. Manufacture today is by extraction and chromatographic isolation from Coptis rhizome for use as an analytical reference standard and research chemical; there is no commercial total-synthesis route in the accessible literature, and — as a minor alkaloid — it is not produced at scale the way berberine is.

Patents: not yet researched.

Toxicity & Safety

Epiberberine carries a low toxicity flag: it is a food-adjacent Coptis alkaloid consumed for centuries as a minor component of goldthread, and no isolate-specific toxicity syndrome is described. The badge is low with a caveat — the dedicated safety dataset is thin, and the clearest concern is a drug-interaction signal rather than direct organ toxicity.

Safety at a Glance

✅ Low / no toxicityDrug interactions

• No isolate-specific toxicity syndrome described. A minor alkaloid of a long-used botanical, studied so far only at research doses in cells and rodents.
• CYP2C9 / CYP2D6 inhibition. Epiberberine noncompetitively inhibits these drug-metabolising enzymes (more strongly in human than rat microsomes), so it could in principle raise levels of drugs cleared by them ^{6Reference 6Chen N et al. · 2018In vitroThe oral bioavailability, excretion and cytochrome P450 inhibition properties of epiberberine: an in vivo and in vitro evaluationView study →}.
• Data are preclinical and sparse. No human safety studies of isolated epiberberine; absence of reported harm is not evidence of safety.
• Protoberberine-class caution by analogy. Its isomer berberine is contraindicated in pregnancy/neonates (bilirubin displacement); epiberberine has not been tested for this, so class caution is prudent — the pregnancy decision belongs to the herb/product page, not this molecule page.

Dosage

There is no established or recommended human dose for isolated epiberberine. The cited efficacy figures are preclinical research doses — commonly around 50–200 mg/kg in mice for the metabolic and anti-H. pylori work ^{2,3,4Reference 2Zhang S et al. · 2024AnimalActivation of NRF2 by epiberberine improves oxidative stress and insulin resistance in T2DM mice and IR-HepG2 cells in an AMPK-dependent mannerView study →Reference 3Xiao Y et al. · 2021Epiberberine ameliorated diabetic nephropathy by inactivating the angiotensinogen (Agt) to repress TGFβ/Smad2 pathwayView study →Reference 4Zhou LM et al. · 2023Epiberberine regulates lipid synthesis through SHP (NR0B2) to improve non-alcoholic steatohepatitisView study →} — and are not convertible to human self-dosing. Real human exposure is indirect: epiberberine is taken only as one of several alkaloids in goldthread (Coptis / Huanglian) crude drug and its traditional formulas, where berberine is the dominant alkaloid and the amount of epiberberine delivered is small ^{7,8Reference 7Lv X et al. · 2016Integration of HPLC-based fingerprint and quantitative analyses for differentiating botanical species and geographical growing origins of Rhizoma coptidisView study →Reference 8Meng FC et al. · 2018Coptidis rhizoma and its main bioactive components: recent advances in chemical investigation, quality evaluation and pharmacological activityView study →}. These are doses studied in research and are not a personal recommendation.

References

1. Wu H, Xie X, Tang Q, Huang T, Tang X, Jiao B, Wang R, Zhu X, Ye X, Ma H, Li X. (2024). Epiberberine inhibits Helicobacter pylori and reduces host apoptosis and inflammatory damage by down-regulating urease expression — in vitro and mouse model. Journal of Ethnopharmacology. https://pubmed.ncbi.nlm.nih.gov/37586440/
2. Zhang S, Zhang S, Zhang Y, Wang H, Chen Y, Lu H. (2024). Activation of NRF2 by epiberberine improves oxidative stress and insulin resistance in T2DM mice and IR-HepG2 cells in an AMPK-dependent manner. Journal of Ethnopharmacology. https://pubmed.ncbi.nlm.nih.gov/38382657/
3. Xiao Y, Deng J, Li C, Gong X, Gui Z, Huang J, Zhang Y, Liu Y, Ye X, Li X. (2021). Epiberberine ameliorated diabetic nephropathy by inactivating the angiotensinogen (Agt) to repress TGFβ/Smad2 pathway. Phytomedicine. https://pubmed.ncbi.nlm.nih.gov/33571918/
4. Zhou LM, Fan JH, Xu MM, Xiong MY, Wang QJ, Chai X, Li XD, Li XG, Ye XL. (2023). Epiberberine regulates lipid synthesis through SHP (NR0B2) to improve non-alcoholic steatohepatitis. Biochimica et Biophysica Acta — Molecular Basis of Disease. https://pubmed.ncbi.nlm.nih.gov/36638873/
5. Kong XP, Liu EYL, Chen ZC, Xu ML, Yu AXD, Wu QY, Xia YJ, Duan R, Dong TTX, Tsim KWK. (2019). Synergistic inhibition of acetylcholinesterase by alkaloids derived from Stephaniae Tetrandrae Radix, Coptidis Rhizoma and Phellodendri Chinensis Cortex. Molecules. https://pubmed.ncbi.nlm.nih.gov/31847089/
6. Chen N, Yang XY, Guo CE, Bi XN, Chen JH, Chen HY, Li HP, Lin HY, Zhang YJ. (2018). The oral bioavailability, excretion and cytochrome P450 inhibition properties of epiberberine: an in vivo and in vitro evaluation. Drug Design, Development and Therapy. https://pubmed.ncbi.nlm.nih.gov/29343943/
7. Lv X, Li Y, Tang C, Zhang Y, Zhang J, Fan G. (2016). Integration of HPLC-based fingerprint and quantitative analyses for differentiating botanical species and geographical growing origins of Rhizoma coptidis. Pharmaceutical Biology. https://pubmed.ncbi.nlm.nih.gov/27569515/
8. Meng FC, Wu ZF, Yin ZQ, Lin LG, Wang R, Zhang QW. (2018). Coptidis rhizoma and its main bioactive components: recent advances in chemical investigation, quality evaluation and pharmacological activity. Chinese Medicine. https://pubmed.ncbi.nlm.nih.gov/29541156/

View all 8 references▾